<DOC>
	<DOCNO>NCT00294008</DOCNO>
	<brief_summary>This study non-interventional web base registry design assess demographic , treatment outcome data patient receive treatment long-acting injectable risperidone . One year retrospective data 2 year prospective data collect .</brief_summary>
	<brief_title>A Study Evaluate Treatment Adherence Schizophrenia With Long Acting Risperidone Microspheres ( e-STAR )</brief_title>
	<detailed_description>This study multicentre , retrospective prospective observational , cohort design , determine aggregate drug usage pattern commonly use clinical outcome associate use long-acting injectable risperidone . The objective study collect sufficient retrospective outcome data allow evaluation treatment outcomes long act medication compare previous treatment document clinical effectiveness long-term treatment outcome actual practice . Additional objectives prospectively assess medication usage pattern evaluate reason initiation and/or discontinuation new antipsychotic medication . The study design non-interventional , single-arm , observational survey use long-acting injectable risperidone long-acting ( depot ) oral atypical antipsychotic , aim ass patient outcomes exist risk disease factor , patient characteristic , previous medication . Having reach agreement patient start treatment long-acting injectable risperidone , physicians opportunity document patient 's clinical data Registry . At baseline , data collect retrospectively minimum period 12-months per patient . Data collect prospectively 24-month period per patient approximately 3-month interval start treatment . This study document data patient treatment new antipsychotic medication indicate , treat accord local label . The start date collect data date new antipsychotic treatment initiate , whether inpatient outpatient . The precede 12 month next 2 year respectively patient retrospective prospective period interest . All patient start new antipsychotic medication , decide agreement physician patient , accordance local label , eligible inclusion survey . While patient participate randomized clinical trial exclude , participation note . Data enter treat physician . All data collect must result normal medical care patient . No intervention treatment decision permit . The patient 's baseline data collect within first week follow initiation new antipsychotic treatment . Prospective data collection occur 3 month , 6 month , 9 month , 12 month , 15 month , 18 month , 21 month 24 month initiation new antipsychotic treatment . If patient stop newly initiate antipsychotic treatment reason discontinuation report . Patients discontinue newly initiate antipsychotic treatment continue follow 24 month . In retrospective period follow treatment outcome assess : patient characteristic , treatment history antipsychotic concomitant medication , hospitalization history , reason initiate new antipsychotic treatment , treatment satisfaction , remission , clinical global impression ( CGI-severity ) , global assessment functioning ( GAF ) clinical deterioration . In prospective period clinical effectiveness assess follow : employment status , remission , treatment satisfaction , CGI-severity , GAF , clinical deterioration , hospitalization , treatment adherence ( serious ) adverse event . Long-acting injectable risperidone flexible dose ( 25mg 75mg ) , intramuscular injection give gluteus 24 month</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients start treatment new antipsychotic medication Permitted physician participate clinical trial Patients schizophrenia schizoaffective disorder Patients ambulant chronically hospitalize maximal 6 month moment initiation study Patients and/or his/her relative , guardian legal representative sign informed consent form First antipsychotic treatment ever Participating drug study Chronically hospitalize accord physician possibility discharge within plan observation period On clozapine last 3 month Serious unstable medical condition , include recent present clinically relevant laboratory abnormality Previous sensitivity history risperidone treatment resistant schizophrenia Pregnant breastfeed female Female plan pregnancy within two year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Treatment adherence</keyword>
	<keyword>Antipsychotic agent</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Long-acting injectable</keyword>
	<keyword>Risperdal tablet</keyword>
	<keyword>Risperidal Consta</keyword>
</DOC>